The Pan-European company develops AI-enabled regulatory and quality automation to make healthcare innovation scalable, efficient, and affordable.
<aside> 💡
Vienna, February 2026 — Flinn, the leading provider of AI-powered software for automating regulatory and quality processes in MedTech, today announced that it has received $20 million in additional funding. The round was led by HV Capital, followed by US based healthcare specialist BHI - Bertelsmann Healthcare Investments with continued support from existing investors Cherry Ventures, Speedinvest, and SquareOne.
With the new funding, Flinn will expand its platform across the entire product lifecycle in MedTech and Pharma covering research and development, commercial and post-market processes. The company will also deepen its presence across Europe and enter the US market, addressing the global need for scalable, compliant, and cost-efficient healthcare innovation.
Addressing exploding healthcare costs through automation
Healthcare systems worldwide are under immense pressure. Aging populations, increasingly complex therapies, and administrative inefficiencies are pushing public healthcare budgets to their limits. Governments are struggling to absorb these costs, while patients face the growing risk of reduced access to cutting-edge treatments or higher out-of-pocket expenses.
Medical devices and pharmaceuticals play a critical role in bending this cost curve through robotized healthcare, advanced diagnostics, and personalized treatments. However, innovation in these sectors is constrained by some of the most stringent regulatory and quality requirements of any industry. While essential for patient safety, these frameworks often slow down innovation and significantly increase the cost of bringing products to market and sustaining compliance across their entire lifecycle.
This is precisely where Flinn creates impact.
Efficiency and innovation through automating compliance
Flinn is transforming how regulated MedTech and Pharma companies manage quality and compliance. Its AI-driven software automates regulatory workflows, data evaluation, and reporting. This way, manual, document-heavy processes are replaced by scalable, intelligent systems.
By embedding automation directly into regulatory and quality functions, Flinn enables manufacturers to operate more efficiently, shorten development cycles, and remain fully compliant without compromising patient safety. What was once a bottleneck becomes a competitive advantage, allowing teams to focus on innovation rather than administration.
Today, leading MedTech companies such as Carl Zeiss, Philips or Paul Hartmann rely on Flinn to manage growing regulatory complexity while maintaining the highest quality standards across global markets. “At Paul Hartmann, Flinn has fundamentally changed how we approach regulatory and quality work,” said Stefan Fischer, Senior VP Regulatory Affairs at Hartmann. “By automating recurring compliance and evaluation tasks, our teams can operate more consistently across markets and focus on higher-value activities that require expert judgment. This level of scalability is becoming essential as regulatory requirements continue to grow in both scope and complexity.”
Strategic expansion across the product lifecycle
With the additional $20 million in funding, Flinn will develop new product capabilities beyond its existing regulatory and post-market solutions. The company will apply automation to earlier development stages and commercial processes, creating a unified compliance and quality backbone throughout the entire lifecycle of a medical product. This expansion is paired with international growth, leveraging the deep industry networks and global experience of HV Capital and Bertelsmann Investments to scale Flinn’s impact across Europe and the United States.